Market Quick Take - April 17, 2020 Market Quick Take - April 17, 2020 Market Quick Take - April 17, 2020

Market Quick Take - April 17, 2020

Macro 3 minutes to read
Steen Jakobsen

Chief Economist & CIO

Summary:  The late market rally has extended further overnight in the wake of the US President Trump plan for phased reopening of the US economy, but even more so in late hours on reports that a drug from Gilead has been proving successful in treating Covid19 patients. We look forward to an interesting session ahead of the weekend, particularly for gold prices, as the recent gold narrative has come under pressure.

The market continues to look through terrible data, including yesterday’s US jobless claims and weak Chinese GDP and Retail Sales data, and is trading at new local highs on anticipation of economies reopening and hopes that a new drug treatment will help lift longer term uncertainty about the Covid19 pandemic.

What is our trading focus?

  • XAUUSD (spot Gold) – the latest sentiment drift to the positive side and narrative that a plan to return to normal is now afoot are seeing spot gold trading back through 1700 technical support. This will be a key test of sentiment given the amount of buying that occurred following the latest Fed bailout. Support at $1680 and $1650.
  • US500.I (US S&P500 Index) – the action in the big tech stocks was unrelenting recently, with the broader market participating less enthusiastically in the recent rally. But overnight, the S&P 500 futures have outperformed the tech-heavy Nasdaq 100 by a solid margin as we watch whether this rally in stocks broadens. The next key US S&P 500 level is around 2930, the 61.8% retracement of the entire sell-off wave.
  • USDCAD – in FX, the USD remains negatively correlated with risk appetite and the USDCAD pair is an interesting to watch whether this latest surge in hope over the progress of reopening and Covid19 treatment can fully reverse can send he pair back toward the recent lows around 1.3855. CAD also captures any strength or weakness in forward crude oil prices, a key sign of whether the market sees production cuts reining in further downside risk.
  • Gilead Sciences (GILD:xnas) – this stock will receive intense focus today after a report from a medical news publication Stat cited a video made by an infectious disease researcher at the University of Chicago who reported that patients (apparently a selection of 125 with severe Covid19 symptoms) being treated with Gilead’s Remdesivir were “seeing rapid recoveries in fever and respiratory symptoms”, with most patients discharged and only two patients dying - shares rose 10% in extended trading yesterday on the news. It has been highlighted that the news hit the wire just after the close when liquidity was thin, and that the author on Stat has before been part of investigations around exaggerated news. A lot of call option activity with strike $80 and short expiry happened just before the release. Studies from China never found anything conclusive on Remdesivir so we encourage clients to hesitate putting too much weight on this event.
  • Schlumberger (SLB:xnys) – first US energy related company (services) to report Q1 earnings with everyone curious about the outlook from an oil services company on the ground. Consensus is looking for revenue to decline 4% y/y and EPS to decline by 19% y/y. With a 12-month trailing dividend yield of 15% it’s almost a given that the company will cut dividends, but the main question is by how much?

What is going on?

French President Macron sends a loud signal on the EU: In an interview with the FT, Macron loudly criticized the position of the economically stronger EU countries’ response to the Covid19 crisis and demanded that the EU do better. This is an important political signal as we ponder whether the EU is slipping into a new existential crisis:

For Mr Macron, the richer EU members have a special responsibility in the way they deal with this crisis. “We are at a moment of truth, which is to decide whether the European Union is a political project or just a market project. I think it’s a political project . . . We need financial transfers and solidarity, if only so that Europe holds on,” he says.

Covid19: US President Trump unveiled a three phase plan for reopening the US economy that local authorities could employ depending on the severity of local outbreaks of the Covid19 pandemic. Trump claimed as many as 29 states may be ready for Phase 1 within the week, which still only allows gatherings of 10 people or fewer and leaves schools closed. A downward trajectory in cases must be documented for two weeks before starting reopening.

Successful new Covid19 treatment? A report that some Chicago patients were showing rapid recovery from Covid19 symptoms after treatment with a Gilead Sciences drug emerged late yesterday and may have driven the large further rise in equities futures into this morning.

US Minneapolis Fed president Kashkari wrote an op-ed telling banks that suspending dividends and raising equity is the appropriate course of action here. In a day of strong gains for the market, this spooked financial stocks, particularly banks, where share prices dropped across the board.

The latest weekly US jobless claims report showed 5.2 million workers applied for claims for the first time, taking the total beyond 22 million for the past four weeks and estimates circulated that the US April unemployment rate could spike to as high as 20%.

Chinese economy shrank in Q1: China reported a Q1 GDP of -6.8% year-on-year, worse than the -6.0% expected. China’s March Industrial Production was reported down -1.1% year-on-year and Mar. Retail Sales at -15.8%.


What we are watching next?

Gold prices – stocks rallying is one thing, but the massive official response in cutting rates and bringing unprecedented policy support to the economy has seen gold only easing off the highs here. Gold price movements in the coming sessions help tell us whether the macro narrative is really buying into the outlook for normalization, with the first test around 1700 in spot gold now unfolding.

Stock market strength broadening or not?  As we discuss above with the strong S&P500 comeback overnight, the broader market has not shown enthusiastic participation in this rally, a situation that needs to change if the rally is to appear more healthy. A bit of extra focus on the worst hit industries as well might be merited today and earlier next week – names like Disney (DIS:xnys), Boeing (BA:xnys) and Marriott Hotels (MAR:xnys), for example.

Natural gas continues to find buyers below $1.60. It bounced strongly on Thursday despite a bigger-than-expected weekly inventory build. The combination of colder-than-normal end of April weather combined with ongoing shut-ins of shale oil wells adding support. Especially the latter need to be watch for signs of bottoming natural gas market.

Economic Calendar (times GMT)

  • 1300 – US St. Louis Fed President Bullard to speak at “Reinventing Bretton Woods Committee Seminar”– this won’t be a market mover, but any signals from the Fed on how it views the dysfunction of the USD as global currency and in effect, how it forces the Fed to act as the world’s bank is interesting. This crisis has laid bare once again that the USD as global money system doesn’t work.

Follow SaxoStrats on the daily Saxo Markets Call on your favorite podcast app:

Apple Sportify Soundcloud Stitcher


Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (
- Analysis Disclaimer (
- Notification on Non-Independent Investment Research (

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.